EDMONTON, Alberta, May 31 /PRNewswire-FirstCall/ -- Medical Services International Inc. (OTC:MSITF) is pleased to announce that while it has been approved to sell VScan HIV test kits in Ukraine since June 2005, it has just received the official report related to the testing that was completed by the health authorities in Ukraine. The report shows that the VScan HIV test kits had a Specificity of 100% and a Sensitivity of 99.8%. This report continues to show how well the VScan HIV test kit performs. This report combined with other test results from European health authorities will be used in the application for CE approval in the European Union. It is anticipated that the report will be submitted within the next two weeks. Approval in the European Union will allow the company to market its VScan HIV test kit in another 26 countries. Preliminary market studies indicate that the company will sell in excess of 1.5 million kits in the first year after receiving approval. The outstanding test results obtained in Eastern Europe are the reason that the VScan test kits are receiving such a positive response. About VScan The VScan rapid test kit is a single use, easy to use, test for the screening of HIV 1&2, Hepatitis B&C, Tuberculosis (TB), Dengue Fever, Malaria, West Nile, and Prostate Cancer. The kits cannot be sold in Canada. Medical Services International Inc. trades in the United States on the NQB Pinksheets under the symbol "MSITF". For further information, please contact Robert Talbot at (780) 430 6363 or http://www.medicalservicesintl.com/ or http://www.minerva-biotech.com/ . NOTE: Certain statements in this press release are "forward-looking statements" within the meaning of the Private Securities Act of 1995. Such statements involve known and unknown risks, uncertainties and other factors that may cause results to differ materially. Such risks, uncertainties and other factors include but are not limited to new economic conditions, risk in product development, market acceptance of new products and continuing product demand, level of competition and other factors described in Company reports and other filings with regulatory bodies. DATASOURCE: Medical Services International Inc. CONTACT: Robert Talbot of Medical Services International Inc., +1-780-430-6363 Web site: http://www.medicalservicesintl.com/ http://www.minerva-biotech.com/

Copyright